ChiCTR2600127431 Neoadjuvant therapy of combined thermal and cold ablation combined with teriprizumab and chemotherapy Resectable Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026
Turn a newly registered trial into a decision-ready landscape. This focused report examines ChiCTR2600127431—A multicenter, single-arm, prospective Phase II clinical trial to evaluate the safety and efficacy of composite cryoablation and hyperthermia ablation combined with toripalimab and neoadjuvant chemotherapy for partially resectable Stage IB-IIIB non-small cell lung cancer—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why ChiCTR2600127431 is a hot trial to watch
Resectable Lung Non-Small Cell Carcinoma is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. ChiCTR2600127431 is notable because it evaluates Neoadjuvant therapy of combined thermal and cold ablation combined with teriprizumab and chemotherapy in a Phase 2 design while Pathological detection serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.
PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | ChiCTR2600127431 |
| Official title | A multicenter, single-arm, prospective Phase II clinical trial to evaluate the safety and efficacy of composite cryoablation and hyperthermia ablation combined with toripalimab and neoadjuvant chemotherapy for partially resectable Stage IB-IIIB non-small cell lung cancer |
| Phase / status | Phase 2 / Not yet recruiting |
| Intervention | Neoadjuvant therapy of combined thermal and cold ablation combined with teriprizumab and chemotherapy, 复合冷热消融联合特瑞普利单抗和化疗新辅助治疗 |
| Sponsor | Not reported |
| Collaborators | Not reported |
| Geography | China |
| Enrollment | 40 |
| Primary endpoint | Pathological detection |
| Endpoint time frame | After lung cancer surgery |
| Primary completion / readout proxy | [object Object] |
Design and endpoint interpretation
The phase label is only the starting point. Allocation is Not reported, masking is NA, and the intervention model is Single Group Assignment. Planned enrollment of 40 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary: Pathological detection (After lung cancer surgery)
- Secondary: Improve objective imaging or pathological examination (Before surgery)
- Secondary: Pathology confirmed that the tumor was completely resected with negative margins and no invasion (After lung cancer surgery)
- Secondary: Time from enrollment to death due to any cause (Time from enrollment to death due to any cause)
- Secondary: The proportion of viable tumor cells ≤ 10% in the resected primary tumor and all lymph nodes (After completion of neoadjuvant therapy)
Benchmark readouts in the surrounding field
- A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors (Phase 2): Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator = 0.69 proportion of participants (95% Confidence Interval, 0.57 - 0.78); Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator = 0.70 proportion of participants (95% Confidence Interval, 0.46 - 0.79)
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)
- A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women (Phase 2): Interval From First Dose to Evidence of Ovulation.(Mean) = 2.67 Number of days (Standard Deviation, 1.53); Interval From First Dose to Evidence of Ovulation.(Mean) = 4.0 Number of days (Standard Deviation, 0)
These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.
Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Not reported
Company & Deal Intelligence context: Not reported
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: comparative data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.
Bottom line
ChiCTR2600127431 is a focused lens on Resectable Lung Non-Small Cell Carcinoma development. Its value will be determined by whether Neoadjuvant therapy of combined thermal and cold ablation combined with teriprizumab and chemotherapy can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
